ArticleJournal of research in medical sciences : the official journal of Isfahan University of Medical Sciences2026
Evaluation of Fibrosis-4 Index, nonalcoholic fatty liver disease fibrosis score, and aspartate aminotransferase-to-platelet ratio index as noninvasive indicators of fibrosis in patients with nonalcoholic fatty liver disease.
Article in Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple noninvasive scoring models have been internationally established and verified for assessing the risk of liver fibrosis in nonalcoholic fatty liver disease (NAFLD) patients. This study aimed to assess the performance of Fibrosis-4 (FIB-4) Index, NAFLD fibrosis score (NFS), and aspartate aminotransferase-to-platelet ratio index (APRI) in individuals with NAFLD. Materials and Methods: We conducted a retrospective chart audit of 211 patients with histologically confirmed NAFLD, focusing on clinical presentation, laboratory parameters, and hepatic histology. Liver fibrosis was graded using the Scheuer classification system. The diagnostic accuracy of the noninvasive tests was evaluated, and revised fibrosis score thresholds. These cohort-derived thresholds may help inform local risk stratification in patients with NAFLD, but external validation is required before clinical use. Results: Among the cohort, fibrosis was staged as follows: 5.7% showed no fibrosis (F0), 56.9% had mild portal expansion (F1), 21.8% exhibited periportal septa (F2), 10.9% displayed architectural distortion without cirrhosis (F3), and 4.7% presented with definite cirrhosis (F4). After threshold optimization, the FIB-4 and NFS models reached the area under the receiver operating characteristic curve (AUROCs) of 0.81 (95% confidence interval [CI]: 0.743-0.867) and 0.79 (95% CI: 0.728-0.852) for identifying significant fibrosis, surpassing the 0.70 (95% CI: 0.629-0.773) recorded for APRI. Significant differences in the AUROCs were observed among the three scores. Similarly, for advanced fibrosis, FIB-4 (AUROC: 0.91, 95% CI: 0.869-0.951) and NFS (AUROC: 0.90, 95% CI: 0.851-0.948) significantly outperformed APRI (AUROC: 0.75, 95% CI: 0.672-0.837; both Conclusion: Modification of the threshold values for FIB-4, NFS, and APRI may enhance the diagnostic performance in patients with NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.